

Emerald BioStructures and Emerald BioSystems Emerald Companies acquired by Beryllium, LLC. Now independent of deCODE genetics, Inc.

November 13, 2009 (Bainbridge Island, Washington)

Today, Emerald BioStructures (formerly deCODE biostructures) and its sister organization Emerald BioSystems, announced that they have become independent and separate from deCODE genetics, Inc.

Emerald BioStructures and Emerald BioSystems have been acquired by Beryllium LLC, a Delaware Limited Liability Company. Financial details were not disclosed. Beryllium LLC and the Emerald companies are owned and financed by a group of strong investors including Gemini Investors, Kendall Square Partners, Eastern Growth Capital II, Arctaris Co-Investment Limited Partnership, and FORMA Therapeutics, Inc.

Lance Stewart, Ph.D. MBA has been named as the Chief Executive Officer of both Emerald Companies. Dr. Stewart is a founder of Emerald BioStructures and has led its operations since its inception. Management is committed to serving a global customer base with world class service that customers have come to expect from Emerald. Now as an independent company, Emerald is ready to expand its customer base and drug discovery services in the challenging field of gene-to-structure research.

About Emerald BioStructures:

One of the largest gene-to-structure contract research organizations in the US, Emerald BioStructures (formerly deCODE biostructures) has 12 years of experience providing collaborative drug discovery research services to pharmaceutical companies, biotechnology companies, academic institutions, and government facilities. Emerald BioStructures operates a high throughput platform that is leveraged for fragment based lead discovery and structure based drug design through numerous collaborations including the Seattle Structural Genomics Center for Infectious Disease (www.SSGCID.org) and the Accelerated Technologies Center for Gene to 3D Structure (www.ATCG3D.org).
<http://www.emeraldbiostructures.com/>

About Emerald BioSystems:

Emerald BioSystems is a leading provider of sophisticated laboratory automation, bioinformatics software, reagent kits and plastic-ware products to structural biologists. Emerald's research tools accelerate the gene-to-protein-structure determination process through advanced computer aided gene design, automated cell-free protein expression, protein purification, and crystallization. A high level of efficiency for protein crystal generation can be achieved using Emerald's novel Microcapillary Protein Crystallization System (MPCS™) Plug Maker™ and CrystalCards™ for nanovolume microfluidic crystallization.

<http://www.emeraldbiosystems.com/>